The University at Buffalo’s Center for Integrated Biomedical Sciences signed yet another deal with The Center for Discovery (TCFD). TCFD is a New York State Center of Excellence that provides medical care and educational services for individuals with developmental disabilities.
Part of the deal includes plans to investigate cannabinoids in Autism Spectrum Disorder (ASD) and drug-resistant epilepsy.
ASD is a developmental disability affecting communication and behavior. Individuals with ASD are more likely to have epilepsy compared to the general population. Previous studies investigating cannabinoids for ASD have shown promise.
The collaboration will also leverage TCFD data to conduct and grow translational research programs.